Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
54 participants
INTERVENTIONAL
2024-03-01
2025-10-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
NCT05794139
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
NCT05517603
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
NCT04944940
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
NCT02024932
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
NCT02644668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NIDO-361
Participants receive 100 mg of NIDO-361 given orally once daily.
NIDO-361
Tablets containing 100mg of NIDO-361 for oral administration.
Placebo
Participants receive matched dose placebo given orally once daily.
Placebo
Placebo oral tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NIDO-361
Tablets containing 100mg of NIDO-361 for oral administration.
Placebo
Placebo oral tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented SBMA diagnosis confirmed by DNA genetic testing
* Able to complete six-minute walk test (6MWT)
Exclusion Criteria
* Inability to undergo MRI (mild sedation may be allowed)
18 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nido Biosciences, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center
Copenhagen, , Denmark
IRCCS Istituto Neurologico Carlo Besta
Milan, , Italy
Azienda Ospedale Università di Padova
Padua, , Italy
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
University of College London Hospital (UCLH)
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDO-361-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.